ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals known as phytochemicals , chemistry and analytical testing services, and product regulatory and safety consulting known as Spherix Consulting . As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP backed ingredient technologies. We then utilize our in house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN nicotinamide riboside pTeroPure pterostilbene PURENERGY, a caffeine pTeroPure co crystal ProC G, a natural black rice containing cyanidin glucoside IMMULINA , a spirulina extract and Suntava Purple Corn derived from a proprietary non GMO purple corn hybrid which contains an extraordinarily high level of anthocyanins. To learn more about ChromaDex, please visit www.ChromaDex.com.
Quote | ChromaDex Corporation (NASDAQ:CDXC)
Last: | $2.775 |
---|---|
Change Percent: | -1.09% |
Open: | $2.79 |
Close: | $2.775 |
High: | $2.84 |
Low: | $2.74 |
Volume: | 166,959 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
News | ChromaDex Corporation (NASDAQ:CDXC)
2024-07-19 14:40:20 ET More on HSBC Holdings, Otis Worldwide HSBC: Q2 2024 Earnings Preview, Investment Case Remains Geared To Income Otis Worldwide: Solid Fundamentals And Growth Levers, But Highly Valued, Hold HSBC: Limited Upside Potential With Some Headwinds (Rat...
2024-07-17 06:39:26 ET More on ChromaDex ChromaDex: Looking To Take The Big Step Into Pharma Seeking Alpha’s Quant Rating on ChromaDex Historical earnings data for ChromaDex Read the full article on Seeking Alpha For further details see: Ch...
Message Board Posts | ChromaDex Corporation (NASDAQ:CDXC)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CDXC News Article - ChromaDex to Report First Quarter 2023 Financial Results on Wednes | whytestocks | investorshangout | 05/02/2023 7:55:52 PM |
whytestocks: $CDXC News Article - ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial | whytestocks | investorshangout | 02/27/2023 1:50:47 PM |
https://healthnews.com/longevity/longevity-supplements/can-nmn-supplements-cause | oilin07 | investorshub | 02/25/2023 1:33:55 PM |
whytestocks: $CDXC News Article - ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotina | whytestocks | investorshangout | 02/22/2023 6:20:47 PM |
Article on Google trending news indicated that this | tat4tat | investorshub | 11/16/2022 1:41:19 AM |
News, Short Squeeze, Breakout and More Instantly...
ChromaDex Corporation Company Name:
CDXC Stock Symbol:
NASDAQ Market:
ChromaDex Corporation Website:
U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper...
ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen ® supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD +...
NR improved the six-minute walking distance and treadmill walking time for those with PAD ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research, shares results from a milestone phase II clinical study showcasing the promising effe...